V-Ha-ras gene expression in liver and kidney of transgenic Tg.AC mice following chemically induced tissue injury.
The dermal Tg.AC transgenic mouse line is currently being used as a short-term alternative in vivo model for carcinogenicity screening of drugs and environmental chemicals. These mice carry multiple copies of an activated v-Ha-ras oncogene, making them susceptible to promotionally induced tumorigenesis caused by carcinogen exposure or deep skin wounding. Transgene expression is associated with tumor development in these animals. To determine whether tissue injury in organs other than the skin can induce transgene expression, we characterized the pattern of transgene expression in naive animals as well as mice treated by oral gavage with cytotoxic doses of chloroform. Hepatic BrdU labeling was increased 40-fold in females (240 mg/kg/day) and 20-fold in males (140 mg/kg/day) after 4 days of dosing with chloroform. An increase in renal BrdU labeling (7-fold) was observed only in male Tg.AC mice. Although chloroform did not induce v-Ha-ras expression, in either the liver or the kidney, a constitutive amount of transgene message was evident in the kidneys of Tg.AC mice. V-Ha-ras transgene expression also correlated with the expression of GATA-3, a transcription factor that binds the zeta-globin (zeta-globin) promoter of the Tg.AC transgene. These studies suggest that chemically induced tissue injury and regenerative cell proliferation per se are not sufficient for the induction of transgene expression in the liver and kidney of Tg.AC mice. Although organs like the kidney may contain the necessary transcription factors for transgene expression, other factors, yet unidentified, may impede v-Ha-ras-mediated tumorigenesis in these tissues.
Delker
D A
DA
The Dow Chemical Company, Health and Environmental Research Laboratory, Midland, Michigan 48674, USA.
Yano
B L
BL
Gollapudi
B B
BB
D000818:Animals; D001973:Bromodeoxyuridine / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002725:Chloroform / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005786:Gene Expression Regulation; D011905:Genes, ras / Q000187:drug effects* / Q000235:genetics; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D008099:Liver / Q000187:drug effects*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D012313:RNA / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction
D012313:RNA; D002725:Chloroform; D001973:Bromodeoxyuridine